ClinicalTrials.gg

Program

BCG Vaccine

Also written as “BCG”, “BCG for Therapeutic Use” and “Bacillus Calmette-Guerin”.

Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms · Urinary Bladder Neoplasms · Tuberculosis · Alzheimer Disease · Melanoma, led by 10 companies.

Furthest: phase 3, since Mar 14, 201616 company-led studies, 8 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Zhifei Biological Products41 open or runningphase 3since Mar 14, 2016Mar 5, 2015Apr 30, 2028phase 3 · NCT06747455
ImmunityBio32 open or runningphase 3since Apr 20, 2026May 13, 2014Nov 2026phase 2 · NCT06829823
Chengdu CoenBiotech21 open or runningphase 3since Jan 28, 2024Jan 28, 2024none ahead
AstraZeneca11 open or runningphase 3since Jul 5, 2023Jul 5, 2023none ahead
Heat Biologics10 open or runningphase 2since Dec 5, 2013Dec 5, 2013none ahead
Laboratorio Pablo Cassará S.R.L.10 open or runningphase 3since Nov 14, 2012Nov 14, 2012none ahead
Merck11 open or runningphase 2since Feb 4, 2025Feb 4, 2025Sep 3, 2031phase 2 · NCT06833073
Mindful Diagnostics and Therapeutics10 open or runningphase 2since Jun 24, 2020Jun 24, 2020none ahead
Pfizer11 open or runningphase 3since Nov 13, 2019Nov 13, 2019none ahead
Verity Pharmaceuticals11 open or runningphase 3since Jul 28, 2021Jul 28, 2021Feb 2029phase 3 · NCT05037279

Also a collaborator on its studies: Moderna, parexel and proswell-medical-corporation.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Nov 14, 2012.

  1. May 13, 2014ImmunityBio's first study: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNew to ImmunityBioImmunityBio · NCT02138734 · 369 enrolled · United States, India, South Africa
  2. Mar 5, 2015Chongqing Zhifei Biological Products's first study: phase 2 study in TuberculosisNew to Chongqing Zhifei Biological ProductsChongqing Zhifei Biological Products · NCT02389322 · 1,044 enrolled · China
  3. Mar 14, 2016Phase 3 study in TuberculosisChongqing Zhifei Biological Products · NCT02795260 · 1,802 enrolled
  4. Nov 13, 2019Pfizer's first study: phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNew to PfizerPfizer · NCT04165317 · 1,068 enrolled · United States, Australia, Belgium and more
  5. Jun 24, 2020Mindful Diagnostics and Therapeutics's first study: phase 2 study in Alzheimer DiseaseNew to Mindful Diagnostics and TherapeuticsMindful Diagnostics and Therapeutics · NCT04449926 · 49 enrolled · United States
  6. Jul 28, 2021Verity Pharmaceuticals's first study: phase 3 study in Urinary Bladder NeoplasmsNew to Verity PharmaceuticalsVerity Pharmaceuticals · NCT05037279 · 540 planned · Canada
  7. Jul 5, 2023AstraZeneca's first study: phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNew to AstraZenecaAstraZeneca · NCT05943106 · 100 enrolled · United States
  8. Oct 13, 2023Phase 1 study in Non-muscular Invasive Bladder CancerChongqing Zhifei Biological Products · NCT06100653 · 10 enrolled · China
  9. Jan 28, 2024Chengdu CoenBiotech's first study: phase 1 study in Urinary Bladder NeoplasmsNew to Chengdu CoenBiotechChengdu CoenBiotech · NCT06350838 · 10 enrolled · China
  10. Jan 28, 2024Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsChengdu CoenBiotech · NCT06241755 · 412 planned · China
  11. Dec 18, 2024Phase 3 study in Urinary Bladder NeoplasmsChongqing Zhifei Biological Products · NCT06747455 · 439 enrolled · China
  12. Feb 4, 2025Merck's first study: phase 2 study in Urinary Bladder NeoplasmsNew to MerckMerck · NCT06833073 · 308 planned · United States, Argentina, Australia and more
  13. Feb 5, 2025Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsImmunityBio · NCT06829823 · 20 planned
  14. Apr 20, 2026Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsPhase 3 reachedImmunityBio · NCT07551544

Ahead

  1. Nov 2026Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsImmunityBio · NCT06829823
  2. Apr 30, 2028Primary completion: phase 3 study in Urinary Bladder NeoplasmsChongqing Zhifei Biological Products · NCT06747455
  3. Feb 2029Primary completion: phase 3 study in Urinary Bladder NeoplasmsVerity Pharmaceuticals · NCT05037279
  4. Sep 3, 2031Primary completion: phase 2 study in Urinary Bladder NeoplasmsMerck · NCT06833073

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities”NCIt, by rule

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07551544Non-Muscle Invasive Bladder Neoplasms3WithdrawnImmunityBioMay 20320
NCT06829823Non-Muscle Invasive Bladder Neoplasms2Not yet recruitingImmunityBioNov 202620
NCT06833073Urinary Bladder Neoplasms · United States, Argentina, Australia and more2RecruitingMerckSep 3, 2031308
NCT06747455Urinary Bladder Neoplasms · China3Active, not recruitingChongqing Zhifei Biological ProductsApr 30, 2028439
NCT06350838Urinary Bladder Neoplasms · China1CompletedChengdu CoenBiotechFeb 13, 202310
NCT06241755Non-Muscle Invasive Bladder Neoplasms · China3RecruitingChengdu CoenBiotechSep 1, 2025412
NCT06100653Non-muscular Invasive Bladder Cancer · China1CompletedChongqing Zhifei Biological ProductsJan 1, 202510
NCT05943106Non-Muscle Invasive Bladder Neoplasms · United States3Active, not recruitingAstraZenecaJun 16, 2025100
NCT05037279Urinary Bladder Neoplasms · Canada3RecruitingVerity PharmaceuticalsFeb 2029540
NCT04449926Alzheimer Disease · United States2CompletedMindful Diagnostics and TherapeuticsDec 4, 202149
NCT04165317Non-Muscle Invasive Bladder Neoplasms · United States, Australia, Belgium and more3Active, not recruitingPfizerDec 2, 20241,068
NCT02795260Tuberculosis3CompletedChongqing Zhifei Biological ProductsOct 20161,802
NCT02389322Tuberculosis · China2CompletedChongqing Zhifei Biological ProductsJul 20151,044
NCT02138734Non-Muscle Invasive Bladder Neoplasms · United States, India, South Africa2Active, not recruitingImmunityBioSep 30, 2026369
NCT02010203Urinary Bladder Neoplasms · United States2TerminatedHeat BiologicsDec 2017104
NCT01729663Melanoma · Argentina3UNKNOWNLaboratorio Pablo Cassará S.R.L.Dec 2018108

How it is read

Names in the registry

  • “BCG”, 4 entries
  • “BCG for Therapeutic Use”, 4 entries
  • “Bacillus Calmette-Guerin”, 1 entry
  • “BCG (50 mg) plus ANKTIVA (400 µg)”, 1 entry
  • “BCG (50 mg)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.